HAVCR2 and cancer: In NSCLC cancer patients that had previously progressed with anti-PD1 treatment alone, combination anti-TIM3 (TSR-022) and anti-PD1 (TSR-042) has shown antitumor activity, as well as safety and tolerability (8).